{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T07:31:06Z","timestamp":1772177466345,"version":"3.50.1"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113999"],"award-info":[{"award-number":["70113999"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SA 1360\/9-3"],"award-info":[{"award-number":["SA 1360\/9-3"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013655","name":"Helmholtz-Fonds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>B-cell acute lymphoblastic leukemia (B-ALL) is characterized by the clonal expansion of immature lymphoblastic cells. Treating patients with disease relapse is challenging, especially after allogeneic stem cell transplantation (aSCT). Although the CD19xCD3 bispecific antibody (bsAb) blinatumomab has improved outcomes for patients with relapsed B-ALL, T cell exhaustion and immune-associated treatment side effects remain problematic. V\u03b39V\u03b42 T cells constitute a relatively small subset in healthy individuals but their abundance increases after aSCT, and higher numbers correlate with improved outcomes. Unlike ab T cells, V\u03b39V\u03b42 T cells are not allo-reactive, do not contribute to graft-versus-host disease and release fewer inflammatory cytokines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using hybridoma technology, we here generated a panel of hybridoma-derived monoclonal antibodies directed against the V\u03b39V\u03b42 receptor that specifically activate V\u03b39V\u03b42 T cells. Subsequently, we generated an IgG-based recombinant CD19x\u03b3\u03b4 bsAb to activate V\u03b39V\u03b42 T cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our bsAb potently induces V\u03b39V\u03b42 T cell activation, proliferation, lysis of B-ALL cell lines in vitro in a dose-dependent manner. Additionally, the bsAb mediates lysis of primary leukemic blasts of patients ex vivo and depletion of CD19-positive target cells in an autologous setting. No significant alphabeta T cell activation or proliferation was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In summary, the selective activation of V\u03b39d\u03b4 T cells using our novel CD19x\u03b3\u03b4 bsAb constitutes a promising immunotherapeutic approach for the treatment of B-ALL. Our results warrant further clinical evaluation especially in patients with minimal residual disease after aSCT or CD3-directed bsAb therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1728424","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:24:34Z","timestamp":1772169874000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Generation and preclinical characterization of a novel bispecific CD19-TCRgammadelta antibody for the treatment of B cell acute lymphoblastic leukemia"],"prefix":"10.3389","volume":"17","author":[{"given":"Joseph","family":"Kauer","sequence":"first","affiliation":[{"name":"Department of Immunology, Interfaculty Institute for Cell Biology, University of T\u00fcbingen","place":["T\u00fcbingen, Germany"]},{"name":"Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital T\u00fcbingen","place":["T\u00fcbingen, Germany"]},{"name":"German Cancer Consortium (DKTK), Partner Site T\u00fcbingen, a Partnership Between DKFZ and University Hospital T\u00fcbingen","place":["T\u00fcbingen, Germany"]},{"name":"Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital","place":["Heidelberg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Vogt","sequence":"additional","affiliation":[{"name":"Department of Immunology, Interfaculty Institute for Cell Biology, University of T\u00fcbingen","place":["T\u00fcbingen, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"H\u00f6rner","sequence":"additional","affiliation":[{"name":"Department of Immunology, Interfaculty Institute for Cell Biology, University of T\u00fcbingen","place":["T\u00fcbingen, Germany"]},{"name":"Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital T\u00fcbingen","place":["T\u00fcbingen, Germany"]},{"name":"German Cancer Consortium (DKTK), Partner Site T\u00fcbingen, a Partnership Between DKFZ and University Hospital T\u00fcbingen","place":["T\u00fcbingen, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital","place":["Heidelberg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[{"name":"Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital","place":["Heidelberg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Raffel","sequence":"additional","affiliation":[{"name":"Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital","place":["Heidelberg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut R.","family":"Salih","sequence":"additional","affiliation":[{"name":"Department of Immunology, Interfaculty Institute for Cell Biology, University of T\u00fcbingen","place":["T\u00fcbingen, Germany"]},{"name":"Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital T\u00fcbingen","place":["T\u00fcbingen, Germany"]},{"name":"German Cancer Consortium (DKTK), Partner Site T\u00fcbingen, a Partnership Between DKFZ and University Hospital T\u00fcbingen","place":["T\u00fcbingen, Germany"]},{"name":"Cluster of Excellence iFIT (EXC 2180), Image-Guided and Functionally Instructed Tumor Therapies, Eberhard Karls University","place":["T\u00fcbingen, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gundram","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Immunology, Interfaculty Institute for Cell Biology, University of T\u00fcbingen","place":["T\u00fcbingen, Germany"]},{"name":"Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital T\u00fcbingen","place":["T\u00fcbingen, Germany"]},{"name":"German Cancer Consortium (DKTK), Partner Site T\u00fcbingen, a Partnership Between DKFZ and University Hospital T\u00fcbingen","place":["T\u00fcbingen, Germany"]},{"name":"Cluster of Excellence iFIT (EXC 2180), Image-Guided and Functionally Instructed Tumor Therapies, Eberhard Karls University","place":["T\u00fcbingen, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Pfl\u00fcgler","sequence":"additional","affiliation":[{"name":"Department of Immunology, Interfaculty Institute for Cell Biology, University of T\u00fcbingen","place":["T\u00fcbingen, Germany"]},{"name":"Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital T\u00fcbingen","place":["T\u00fcbingen, Germany"]},{"name":"German Cancer Consortium (DKTK), Partner Site T\u00fcbingen, a Partnership Between DKFZ and University Hospital T\u00fcbingen","place":["T\u00fcbingen, Germany"]},{"name":"Cluster of Excellence iFIT (EXC 2180), Image-Guided and Functionally Instructed Tumor Therapies, Eberhard Karls University","place":["T\u00fcbingen, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41409-018-0373-4","article-title":"Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"54","author":"Giebel","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.351","article-title":"Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT","volume":"26","author":"Spyridonidis","year":"2012","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell\u2013engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2020009098","article-title":"KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"New Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/0008-5472.CAN-06-3069","article-title":"Perspectives of \u03b3\u03b4 T cells in tumor immunology","volume":"67","author":"Kabelitz","year":"2007","journal-title":"Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(02)00034-2","article-title":"Structure of \u03b3\u03b4 T cell receptors and their recognition of non-peptide antigens","volume":"38","author":"Allison","year":"2002","journal-title":"Mol Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.prp.2011.10.006","article-title":"Transplantation in the onco-hematology field: focus on the manipulation of \u03b1\u03b2 and \u03b3\u03b4 T cells","volume":"208","author":"Daniele","year":"2012","journal-title":"Pathol-Res Pract"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12289","article-title":"The role of gamma delta T cells in haematopoietic stem cell transplantation","volume":"81","author":"Minculescu","year":"2015","journal-title":"Scandinavian J Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1433785","article-title":"Lower incidence of grade II-IV acute Graft-versus-Host-Disease in pediatric patients recovering with high V\u03b42+ T cells after allogeneic stem cell transplantation with unmanipulated bone marrow grafts: a prospective single-center cohort study","volume":"15","author":"M\u00fcller","year":"2024","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.11.6767","article-title":"Characterization of tumor reactivity of human V\u03b39V\u03b42 \u03b3\u03b4 T cells in vitro and in SCID mice in vivo","volume":"173","author":"Kabelitz","year":"2004","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.7150\/ijbs.7823","article-title":"\u03b3\u03b4 T cells and their potential for immunotherapy","volume":"10","author":"Wu","year":"2014","journal-title":"Int J Biol Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2015.04.009","article-title":"\u03b3\u03b4 T cell activation by bispecific antibodies","volume":"296","author":"Oberg","year":"2015","journal-title":"Cell Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7509","article-title":"A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (\u03b3\u03b4) T cells in adults with B-cell Malignancies","volume":"40","author":"Neelapu","year":"2022","journal-title":"Am Soc Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1373","article-title":"Allogeneic CD20-targeted \u03b3\u03b4 T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models","volume":"11","author":"Nishimoto","year":"2022","journal-title":"Clin Trans Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1182\/blood-2021-152028","article-title":"Third-generation chimeric antigen receptor (CAR) T cells in patients with relapsed\/refractory acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL)-results from the Heidelberg trial 1 (HD-CAR-1 trial)","volume":"138","author":"Schubert","year":"2021","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-017-3539-3","article-title":"RNA-transfection of \u03b3\/\u03b4 T cells with a chimeric antigen receptor or an \u03b1\/\u03b2 T-cell receptor: a safer alternative to genetically engineered \u03b1\/\u03b2 T cells for the immunotherapy of melanoma","volume":"17","author":"Harrer","year":"2017","journal-title":"BMC Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01122-7","article-title":"Selective recruitment of \u03b3\u03b4 T cells by a bispecific antibody for the treatment of acute myeloid leukemia","volume":"35","author":"Ganesan","year":"2021","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-0189","article-title":"A bispecific \u03b3\u03b4 T-cell engager targeting EGFR activates a potent V\u03b39V\u03b42 T cell\u2013mediated immune response against EGFR-expressing tumors","volume":"11","author":"King","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aax8861","article-title":"CD3 bispecific antibody\u2013induced cytokine release is dispensable for cytotoxic T cell activity","volume":"11","author":"Li","year":"2019","journal-title":"Sci Trans Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01997","article-title":"Improved overall survival, relapse-free-survival, and less graft-vs.-host-disease in patients with high immune reconstitution of TCR gamma delta cells 2 months after allogeneic stem cell transplantation","volume":"10","author":"Minculescu","year":"2019","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007955","article-title":"Therapeutic avenues for \u03b3\u03b4 T cells in cancer","volume":"11","author":"Costa","year":"2023","journal-title":"J ImmunoTher Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/imm.70035","article-title":"Gamma delta T cells in the tumour microenvironment: A double-edged sword","volume":"177","author":"Hayati","year":"2026","journal-title":"Immunology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.915837","article-title":"Gamma delta T-cell based cancer immunotherapy: past-present-future","volume":"13","author":"Saura-Esteller","year":"2022","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-0675","article-title":"Novel bispecific antibodies increase \u03b3\u03b4 T-cell cytotoxicity against pancreatic cancer cells","volume":"74","author":"Oberg","year":"2014","journal-title":"Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910440210","article-title":"Re-targeting of human lymphocytes expressing the T-cell receptor gamma\/delta to ovarian carcinoma cells by the use of bispecific monoclonal antibodies","volume":"44","author":"Ferrini","year":"1989","journal-title":"Int J Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/2326-6066.CIR-20-0138","article-title":"A bispecific antibody antagonizes prosurvival cd40 signaling and promotes V\u03b39v\u03b42 T cell\u2013mediated antitumor responses in human B-cell Malignancies","volume":"9","author":"De Weerdt","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4576","article-title":"A bispecific single-domain antibody boosts autologous V\u03b39V\u03b42-T cell responses toward CD1d in chronic lymphocytic leukemia","volume":"27","author":"De Weerdt","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2200185","article-title":"Cutting edge: bispecific \u03b3\u03b4 T cell engager containing heterodimeric BTN2A1 and BTN3A1 promotes targeted activation of V\u03b39V\u03b42+ T cells in the presence of costimulation by CD28 or NKG2D","volume":"209","author":"Lai","year":"2022","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.2","article-title":"Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia","volume":"23","author":"Durben","year":"2015","journal-title":"Mol Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911902","article-title":"An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer","volume":"13","author":"Zekri","year":"2021","journal-title":"EMBO Mol Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01089-x","article-title":"Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia","volume":"35","author":"Wei","year":"2021","journal-title":"Leukemia"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006287","article-title":"Tumor-intrinsic and-extrinsic determinants of response to blinatumomab in adults with B-ALL","volume":"137","author":"Zhao","year":"2021","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19104","article-title":"Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study","volume":"203","author":"Ocadlikova","year":"2023","journal-title":"Br J Haematol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000621","article-title":"Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies","volume":"8","author":"Kauer","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.12.001","article-title":"Chimeric antigen receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation","volume":"26","author":"Capsomidis","year":"2018","journal-title":"Mol Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003441","article-title":"Off-the-shelf V\u03b41 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma","volume":"9","author":"Makkouk","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-SITC2020.0101","article-title":"101 Engineering gamma\/delta T cells with the T-Cell antigen coupler receptor effectively induces antigen-specific tumor cytotoxicity in vitro and in vivo","volume":"8","author":"Asbury","year":"2020","journal-title":"BMJ Special J"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3495","article-title":"Arming V\u03b42 T cells with chimeric antigen receptors to combat cancer","volume":"30","author":"Thomas","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2025.03.361","article-title":"Anti-tumor efficacy of Bi-specific antibody complexed gamma delta T cells against multiple myeloma","volume":"27","author":"Hyun","year":"2025","journal-title":"Cytotherapy"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02638-0","article-title":"TIM-3 blockade combined with bispecific antibody MT110 enhances the anti-tumor effect of \u03b3\u03b4 T cells","volume":"69","author":"Guo","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018027003","article-title":"The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia","volume":"3","author":"Yeshurun","year":"2019","journal-title":"Blood Adv"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705650","article-title":"Long term disease-free survival in acute leukemia patients recovering with increased \u03b3\u03b4 T cells after partially mismatched related donor bone marrow transplantation","volume":"39","author":"Godder","year":"2007","journal-title":"Bone Marrow Transpl"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705898","article-title":"Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation","volume":"41","author":"Loren","year":"2008","journal-title":"Bone Marrow Transpl"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02475-0","article-title":"The BLIND study: blinatumomab and DLI approach for management of B-ALL relapse after allogeneic stem cell transplantation. A multicentric Italian experience","volume":"60","author":"Giammarco","year":"2025","journal-title":"Bone Marrow Transpl"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013290","article-title":"Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia","volume":"139","author":"Gaballa","year":"2022","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601100","article-title":"Immune reconstitution after allogeneic hematopoietic stem cell transplantation: time to T up the thymus","volume":"198","author":"Chaudhry","year":"2017","journal-title":"J Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/14653240802419328","article-title":"Zoledronate facilitates large-scale ex vivo expansion of functional \u03b3\u03b4 T cells from cancer patients for use in adoptive immunotherapy","volume":"10","author":"Kondo","year":"2008","journal-title":"Cytotherapy"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0521-6","article-title":"In vivo effects of zoledronic acid on peripheral \u03b3\u03b4 T lymphocytes in early breast cancer patients","volume":"58","author":"Santini","year":"2009","journal-title":"Cancer Immunol Immunother"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1728424\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:24:36Z","timestamp":1772169876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1728424\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2026.1728424"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1728424","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"article-number":"1728424"}}